About 3DHEALS Company Directory:
3DHEALS updates this collection of public and private companies, government and non-government institutions, and any relevant research organizations in healthcare 3D printing, bioprinting, AR/VR, 3D technologies, on a weekly basis. Access to this directory is free to 3DHEALS Premium and Enterprise members.
THIS CONTENT IS FOR PREMIUM AND ENTERPRISE MEMBERS ONLY.

Details
Matricelf developed a technology that enables the production of autologous engineered tissue composed of matrix and cells derived from patients omentum biopsy. The omentum-based hydrogel can be used to create autologous implants, either as bioink for 3D printing of tissues and organs or other tissue engineering methods. The printed tissues and organs can potentially match the immunological, biochemical, and anatomical properties of the patient. The company recently licensed the technology that enabled scientist at Tel Aviv university that 3D printed a human heart from human cells and matrix for the first time in human history. The company plans to conduct its first human clinical trial for Acute Spinal Cord Injury (SCI) in 2024.